On the one hand daratumumab is seen to be rather promising in the treatment of myeloma. On the other hand it (apparently) interferes in performing blood groups on automated systems as it causes panagglutination.
Apparently we are going to be involved in an international study.... I wonder how this will pan out
This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England. One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
No comments:
Post a Comment